Drospirenone - Exeltis USA
Alternative Names: Drospirenone-only pill - Exceltis USA; DRSP-only oral contraceptive - Leon Farma; LF-111; LPRI-CF113; Slinda; SlyndLatest Information Update: 29 Sep 2022
Price :
$50 *
At a glance
- Originator Exeltis USA
- Developer Chemo Research, S.L.; Duchesnay Inc; Exeltis USA; Leon Farma
- Class Androstenes; Antiandrogens; Oral contraceptives; Progesterone congeners
- Mechanism of Action Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pregnancy
- Phase III Endometriosis
Most Recent Events
- 04 Aug 2022 Phase-III clinical trials in Pregnancy (In adolescents, In adults, Prevention) in USA (PO) (NCT05461573)
- 18 Jul 2022 Exeltis USA plans a Phase III trial for Pregnancy (In adolescents, In adults, Prevention)(PO) (NCT05461573) (CF113-303)
- 17 May 2022 Launched for Pregnancy (Prevention) in Canada (PO)